TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3537101
Drug: Saturated solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saturated solution of potassium iodide (SSKI, 12 drops daily for 10 days)
Study: 25031274
Drug: Erlotinib (100mg)
Normalized name: erlotinib 100 MG
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib (100mg) plus WBRT (20 Gy in 5 fractions) followed by maintenance erlotinib (150 mg)
Study: 17973974
Drug: Dextofisopam 200
Normalized name: tofisopam
DrugBank: Tofisopam (DB08811)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Dextofisopam 200 mg b.d. for 12 weeks
Study: 12456597
Drug: Human albumin
Normalized name: Human albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human albumin administration
Study: 12832248
Drug: Individual plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual plus group drug counseling
Study: 12832248
Drug: Other psychosocial
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other psychosocial treatments (not specified)
Study: 2060439
Drug: Metformin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1 g three times daily)
Study: 6650766
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg of furosemide as a bolus injection at time 0 and again 6 hours later
Study: 6650766
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg per hour of furosemide as a constant infusion for 12 hours
Study: 26762988
Drug: BMS-986001 100
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-986001 100 mg once a day
Study: 26762988
Drug: BMS-986001 200
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-986001 200 mg once a day
Study: 26762988
Drug: BMS-986001 400
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-986001 400 mg once a day
Study: 23942319
Drug: Liraglutide 1.2-3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.2-3.0 mg
Study: 23942319
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg × 3 per day
Study: 22978588
Drug: Herbal extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal extract (HEX) at 50 mg/kg diet
Study: 22978588
Drug: Monensin (MON)
Normalized name: Monensin
DrugBank: Monensin (DB11430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monensin (MON) at 100 mg/kg diet
Study: 17006376
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone protein plus soy lecithin (25 g/day + 20 g/day)
Study: 17006376
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone protein (25 g/day)
Study: 17006376
Drug: Soy lecithin
Normalized name: Soy Lecithin
DrugBank: Lecithin, soybean (DB14161)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy lecithin (20 g/day)
Study: 9139527
Drug: Pefloxacin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin (800 mg as single dose)
Study: 9139527
Drug: Ciprofloxacin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (250 mg/8 h/72 h)
Study: 1871323
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release formulation (MPH-IR) with a regular dose of 10mg (n=5) and 5mg (n=1) of methylphenidate (MPH) in the first pilot study.
Study: 1871323
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release formulation (MPH-SR) with a regular dose of 20mg of methylphenidate (MPH) in the second pilot study.
Study: 6384510
Drug: Control (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (group therapy only)
Study: 22859321
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate treatment protocol for acute severe asthma exacerbation
Study: 22859321
Drug: Standard protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard protocol for the initial treatment of acute asthma exacerbation (Control group)
Study: 20301114
Drug: Chemotherapy (cisplatin/fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cisplatin/fluorouracil plus either docetaxel or epirubicin)
Study: 16011771
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (15 teeth) prepared with Hero Shapers and irrigated with 5 mL of EDTA (10%) and 5 mL of 5% NaOCl at 50 degrees C, no electrical pulse treatment
Study: 2358942
Drug: Naproxen sodium,
Normalized name: Naproxen Sodium, sodium compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen sodium, 550 mg administered 30 minutes postoperatively
Study: 2358942
Drug: Naproxen sodium,
Normalized name: Naproxen Sodium, sodium compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen sodium, 550 mg administered 30 minutes preoperatively
Study: 31009339
Drug: Tenecteplase 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenecteplase 0.4 mg/kg
Study: 27521828
Drug: Brief smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief smoking cessation intervention (protocolized counseling, medications, referrals to a quitline)
Study: 24620920
Drug: ADV in
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADV in combination with HB‐110
Study: 21757932
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg) injected through the tonsillar capsule
Study: 19337628
Drug: Oral Buscopan
Normalized name: Buscopan
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Buscopan (20 mg three times a day, n=37)
Study: 19337628
Drug: Buscopan Suppository
Normalized name: Buscopan
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buscopan Suppository (30 mg once daily, n=21)
Study: 19337628
Drug: Oral Drotaverine
Normalized name: drotaverin
DrugBank: Drotaverine (DB06751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Drotaverine (80 mg three times a day, n=30)
Study: 19337628
Drug: Calcium Gluconate
Normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium Gluconate Tablets (one three times a day, n=16)
Study: 19337628
Drug: Calendula Suppository
Normalized name: CALENDULA
DrugBank: Calendula officinalis whole (DB14315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calendula Suppository (once daily, n=14)
Study: 19337628
Drug: Oral Buscopan
Normalized name: Buscopan
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Buscopan
Study: 19337628
Drug: Rectal Buscopan
Normalized name: Buscopan
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal Buscopan
Study: 19337628
Drug: Oral Drotaverine
Normalized name: drotaverin
DrugBank: Drotaverine (DB06751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Drotaverine
Study: 11356239
Drug: Monotherapy (either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (either IPT or NT alone)
Study: 11356239
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment (combined NT and IPT)
Study: 7939146
Drug: Oxymetazoline spray
Normalized name: oxymetazoline Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline spray
Study: 7939146
Drug: Oxymetazoline solution
Normalized name: oxymetazoline Ophthalmic Solution
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxymetazoline solution
Study: 3377149
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion of 0.075% bupivacaine at a rate of 12‐18 ml/hour
Study: 4890523
Drug: Methyldopa (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (high doses)
Study: 28659138
Drug: Comprehensive Geriatric
Normalized name: CATHETER,EXTERNAL CONVEEN #5120 GERIATRIC/PEDIATRIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive Geriatric Assessment (CGA) and intervention before and during chemotherapy
Study: 28659138
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy regimens and standard of care
Study: 21627518
Drug: Nalbuphine HCl
Normalized name: nalbuphine HCl
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalbuphine HCl (12.5 mg/kg) IV administration
Study: 21627518
Drug: Nalbuphine HCl
Normalized name: nalbuphine HCl
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalbuphine HCl (12.5 mg/kg) IM administration
Study: 19531212
Drug: Letrozole (aromatase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (aromatase inhibitor)
Study: 15531673
Drug: l‐rhamnose (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: l‐rhamnose (25 g for 28 days)
Study: 15531673
Drug: lactulose (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactulose (25 g for 28 days)
Study: 7877519
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal oestradiol for 3 months
Study: 7877519
Drug: Cyclical transdermal
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical transdermal oestradiol with medroxyprogesterone acetate for 3 months
Study: 14552308
Drug: Auranofin (AF)
Normalized name: Auranofin
DrugBank: Auranofin (DB00995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auranofin (AF) therapy
Study: 23460707
Drug: Single early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single early intravesical instillation of pirarubicin (THP) 30 mg in 30 mL of saline
Study: 10902988
Drug: E supplement
Normalized name: Iodine supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: E supplement (1171 kJ + 12 mg iron)
Study: 10902988
Drug: M supplement
Normalized name: Sodium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: M supplement (209 kJ + 12 mg iron)
Study: 10902988
Drug: S supplement
Normalized name: Phosphorus supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: S supplement (104 kJ)
Study: 29187694
Drug: 1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day pitavastatin
Study: 29212965
Drug: 2 mg/day
Normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/day pitavastatin
Study: 25330142
Drug: 3 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg/day enteric-coated aspirin tablets for 6 months
Study: 25330142
Drug: 5 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg/day enteric-coated aspirin tablets for 6 months
Study: 21904634
Drug: 0.1% NVC-422
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% NVC-422 topical gel
Study: 21904634
Drug: 0.5% NVC-422
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% NVC-422 topical gel
Study: 21904634
Drug: 1.5% NVC-422
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% NVC-422 topical gel
Study: 21904634
Drug: NVC-422 topical
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVC-422 topical gel (all doses)
Study: 1482300
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) nebulized solution
Study: 30222804
Drug: CLS‐TA (triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLS‐TA (triamcinolone acetonide injectable suspension)
Study: 27287210
Drug: Doxycycline (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (oral, 4 weeks)
Study: 27287210
Drug: Placebo (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral, 4 weeks)
Study: 27287210
Drug: Alclometasone (topical)
Normalized name: alclometasone Topical Cream
DrugBank: Alclometasone (DB00240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alclometasone (topical) plus VSL#3 (oral)
Study: 27287210
Drug: VSL#3 (oral)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VSL#3 (oral)
Study: 25241229
Drug: Chemoradiotherapy (CHRT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (CHRT) with fluorouracil (5 FU) infusion and cisplatin, associated with radiotherapy (50 Gy)
Study: 22857987
Drug: Mental practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mental practice in addition to occupational therapy
Study: 12551706
Drug: Levodopa/benserazide (200/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/benserazide (200/50 mg) with a high-fat breakfast
Study: 12551706
Drug: Levodopa/benserazide (200/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/benserazide (200/50 mg) in fasting conditions
Study: 12551706
Drug: Levodopa/benserazide (200/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/benserazide (200/50 mg) with food
Study: 10513411
Drug: Telviran (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telviran (800 mg acyclovir)
Study: 10513411
Drug: Zovirax (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zovirax (800 mg acyclovir)
Study: 2028627
Drug: SR PPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR PPA 75 mg/d
Study: 6106501
Drug: Combined sedative
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sedative and anxiolytic preparations (specific combinations not detailed)
Study: 6106501
Drug: Amylobarbitone sodium
Normalized name: Amylobarbitone sodium
DrugBank: Amobarbital (DB01351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amylobarbitone sodium (established hypnotic)
Study: 6106501
Drug: Clobazam/dichloralphenazone (anxiolytic/sedative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam/dichloralphenazone (anxiolytic/sedative combination)
Study: 28675660
Drug: First-line intercalated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line intercalated chemotherapy + erlotinib, maintenance erlotinib in patients with EGFR mutations
Study: 28675660
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy + bevacizumab, maintenance bevacizumab in EGFR wild-type patients
Study: 28675660
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + conatumumab, maintenance conatumumab in patients with squamous histology
Study: 28675660
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + cetuximab, maintenance cetuximab or chemotherapy + necitumumab, maintenance necitumumab in EGFR FISH-positive patients with squamous histology
Study: 28675660
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy + bevacizumab, maintenance bevacizumab or first-line sequential chemotherapy + gefitinib, maintenance gefitinib in patients clinically enriched for EGFR mutations with nonsquamous histology
Study: 26393645
Drug: Low-carbohydrate diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate diet (<40 g/day), n = 75
Study: 15385382
Drug: Isobaric 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric 0.5% bupivacaine, 18 mg plus saline (Group 1, control)
Study: 9699431
Drug: Patient-controlled TENS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled TENS at the injection site
Study: 9699431
Drug: Topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthesia (2 min application of 20% benzocaine)
Study: 2513630
Drug: Nonabsorbable agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonabsorbable agents
Study: 1269214
Drug: Experimental soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental soft gelatin formulations of digoxin in solution
Study: 1269214
Drug: Capsules of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules of digoxin
Study: 1269214
Drug: Tablets of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets of digoxin
Study: 12615868
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g every 8 h (C3 x 2)
Study: 12615868
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g as a loading dose, followed by ceftazidime 2 g over 7 h every 12 h (C2 x 2)
Study: 10669372
Drug: Meningococcal AC
Normalized name: meningococcal AC polysaccharide (non-US)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal AC polysaccharide (MACP) vaccine
Study: 26414626
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oxytocin and motherwort injection
Study: 8889352
Drug: Atenolol, Amlodipine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol, Amlodipine, or Enalapril (three antihypertensive drug regimens)
Study: 8889352
Drug: Attendance at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attendance at scheduled monthly follow-up visits
Study: 8889352
Drug: Overall attendance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall attendance and medication adherence
Study: 1984386
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms of hepatitis B vaccine
Study: 6684932
Drug: i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion of 20 mg diltiazem in 20 min
Study: 6684932
Drug: peroral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: peroral solution of 120 mg diltiazem
Study: 6684932
Drug: two 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: two 60 mg tablets of diltiazem (Dilzem)
Study: 29681015
Drug: Cryotherapy (cooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy (cooled glove/sock worn for 15 min before, during, and after paclitaxel infusion)
Study: 25516315
Drug: Probiotics three
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics three times daily for 8 days
Study: 20678136
Drug: Vertical augmentation
Normalized name: Verticalm
DrugBank: Meclizine (DB00737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vertical augmentation with anorganic bovine bone blocks and delayed 5-month placement of ≥10 mm implants
Study: 20678136
Drug: 7-mm-long implants
Normalized name: LONG PEPPER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-mm-long implants
Study: 20678136
Drug: Vertical augmentation
Normalized name: Verticalm
DrugBank: Meclizine (DB00737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vertical augmentation with anorganic bovine bone blocks
Study: 19887674
Drug: Etoricoxib (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (selective COX-2 inhibitor)
Study: 16371185
Drug: Calcium carbonate/cholecalciferol
Normalized name: ipriflavone/calcium carbonate/cholecalciferol (vit D3) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium carbonate/cholecalciferol therapy (calcium carbonate: 1500 mg per day; cholecalciferol 400 UI per day)
Study: 16371185
Drug: Calcium lactogluconate/calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium lactogluconate/calcium carbonate (mg 300 per day)
Study: 2106714
Drug: Cyclic estradiol-desogestrel
Normalized name: desogestrel / ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic estradiol-desogestrel therapy for 6 months
Study: 26910781
Drug: Clindamycin-Gentamicin solution
Normalized name: gentamicin Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin-Gentamicin solution (Group 2)
Study: 19047285
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg on days 1 and 2 with chemotherapy on day 3 (150 PRE)
Study: 19047285
Drug: Erlotinib 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 1,500 mg on days 1 and 2 with chemotherapy on day 3 (1,500 PRE)
Study: 19047285
Drug: Chemotherapy on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy on day 1 with erlotinib 1,500 mg on days 2 and 3 (1,500 POST)
Study: 17606173
Drug: Studies with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Studies with concurrent economic evaluation
Study: 17606173
Drug: Studies without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Studies without concurrent economic evaluation
Study: 9073140
Drug: Intraduodenal triglyceride
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal triglyceride infusion under euglycemic conditions
Study: 9073140
Drug: Intraduodenal triglyceride
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal triglyceride infusion under hyperglycemic conditions
Study: 9073140
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of hyperglycemia vs euglycemia during intraduodenal triglyceride infusion
Study: 7526027
Drug: L-asparaginase (L-ASP)
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-asparaginase (L-ASP) added to consolidation therapy for average risk patients (MRG)
Study: 7526027
Drug: G-CSF administered
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF administered in intervals between intensification elements for high risk patients (HRG)
Study: 7526027
Drug: Initial response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial response to a 7-day exposure to prednisone and first intrathecal injection of MTX
Study: 7526027
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of blasts in the bone marrow (BM) at day 15 of treatment
Study: 7526027
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment protocol including 8-drug induction, consolidation, reinduction, and maintenance therapy
Study: 3319643
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin infusion
Study: 3319643
Drug: Porcine insulin
Normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine insulin infusion
Study: 23447373
Drug: Donepezil (10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (10mg daily for 3 months)